<  Back to Investments


Academic research has identified the molecular genetic background of more than 3,500 inherited diseases. Due to lack of sophisticated enough genetic diagnostics, a large part of patients are left without diagnosis and clinical follow up. Blueprint Genetics is set to change this. The company revolutionises genetic testing by providing clinical genetic diagnostics for professional use.

The proprietary Next-Generation Sequencing (NGS) technology developed in Stanford University allows the team to introduce an unprecedented combination of high sequencing quality, quick lead time & low pricing. In 2013, the company entered the market with its first product category, providing diagnostics for inherited cardiovascular disorders. Today, Blueprint Genetics serves more than 100 hospital customers across 15 countries. The company operates out of Finland & the US.

For more information, please visit http://blueprintgenetics.com